HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.

HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.

We have previously reported on HIV-1 infected patients who fail anti-retroviral therapy but manage to re-suppress without a regimen change despite harbouring major drug resistance mutations. Here we explore phenotypic drug resistance in such patients in order to better understand this phenomenon. Pa...

Full description

Bibliographic Details
Main Authors:	Adriaan E Basson, Salome Charalambous, Christopher J Hoffmann, Lynn Morris
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2020-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0234937

Similar Items

Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression.
by: Patricia Ndumbi, et al.
Published: (2014-01-01)

Early virological suppression despite high frequency NNRTI resistance following perinatal prophylaxis in HIV-infected African infants
by: Coovadia Hoosen, et al.
Published: (2008-04-01)

Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
by: Marta Iglis Oliveira, et al.
Published: (2018-10-01)

An investigation of plant extracts with HIV reverse transcriptase inhibitory activity.
by: Basson, Adriaan Erasmus
Published: (2008)

Human Placental Hofbauer Cells Maintain an Anti-inflammatory M2 Phenotype despite the Presence of Gestational Diabetes Mellitus
by: Carolin Schliefsteiner, et al.
Published: (2017-07-01)

HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation.
by: Adriano Boasso, et al.
Published: (2008-08-01)

Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model.
by: Godfrey A Dzhivhuho, et al.
Published: (2018-07-01)

Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality
by: Roos E. Barth, et al.
Published: (2011-01-01)

Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar
by: Mwinyi Msellem, et al.
Published: (2020-08-01)

Association between time spent with residual viremia after achievement of virological suppression and type of first-line antiretroviral regimen
by: A. Lazzarin, et al.
Published: (2017-12-01)

Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori
by: Tariq H, et al.
Published: (2020-01-01)

Lack of a Clear Behavioral Phenotype in an Inducible FXTAS Mouse Model Despite the Presence of Neuronal FMRpolyG-Positive Aggregates
by: Saif N. Haify, et al.
Published: (2020-12-01)

Significant lung volume reduction with endobronchial valves in a patient despite the presence of microcollaterals masked by low-flow Chartis phenotype
by: Yin Y, et al.
Published: (2016-11-01)

Activation and gut-homing of peripheral T cells in HIV immunologic non-responders despite long term viral suppression.
by: Rodney K Rousseau, et al.
Published: (2021-01-01)

Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1
by: Michael J. Peluso, et al.
Published: (2020-01-01)

An altered cytotoxic program of CD8+ T-cells in HIV-infected patients despite HAART-induced viral suppression.
by: Federico Perdomo-Celis, et al.
Published: (2019-01-01)

Activation of methanogenesis in arid biological soil crusts despite the presence of oxygen.
by: Roey Angel, et al.
Published: (2011-01-01)

A Successful Pregnancy Despite the Presence of an Intrauterine Fetal Bone Fragment
by: Evangelos Petrakis, et al.
Published: (2019-01-01)

Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression
by: Majid Darraj, et al.
Published: (2018-03-01)

Persistence of Activated and Adaptive-Like NK Cells in HIV+ Individuals despite 2 Years of Suppressive Combination Antiretroviral Therapy
by: Anna C. Hearps, et al.
Published: (2017-06-01)

Sustained HIV Viral Suppression with Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
by: Nagami, E.H, et al.
Published: (2022)

Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study
by: Chika K. Onwuamah, et al.
Published: (2020-01-01)

Inequalities in uptake of HIV testing despite scale-up
by: Euphemia L Sibanda, et al.
Published: (2020-06-01)

Incidence and predictors of first line antiretroviral regimen modification in western Kenya.
by: Seth Inzaule, et al.
Published: (2014-01-01)

Regimen durability in HIV-positive children andd adolescents initiating first-line art in a large public sector HIV cohort in South Africa
by: Bonawitz, Rachael
Published: (2019)

Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings
by: Sasisopin Kiertiburanakul, et al.
Published: (2017-05-01)

Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens
by: Aleksey Viktorovich Kravchenko, et al.
Published: (2010-11-01)

Genotype networks of 80 quantitative Arabidopsis thaliana phenotypes reveal phenotypic evolvability despite pervasive epistasis.
by: Gabriel Schweizer, et al.
Published: (2020-08-01)

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
by: Sharlene Ho, et al.
Published: (2020-05-01)

First-Line Antiretroviral Regimen Failure and Determinants in an Urban HIV Clinic at Phramongkutklao Hospital, Bangkok, Thailand: 20 Years Experience
by: Nasomsong W, et al.
Published: (2021-03-01)

Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
by: Kavindhran Velen, et al.
Published: (2013-01-01)

HIV viral transcription and immune perturbations in the CNS of people with HIV despite ART
by: Calvi, R., et al.
Published: (2022)

Malignant adenomyoepithelioma: A tumor of low malignant potential despite basal phenotype
by: Jatin S Gandhi, et al.
Published: (2011-01-01)

Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patients
by: Roberto Ravasio, et al.
Published: (2017-07-01)

High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study.
by: Vennie Mbaziira Nabitaka, et al.
Published: (2020-01-01)

NNRTI-associated mutations in patients with virologic failure on first-line regimen in Yekaterinburg
by: A. Chuykov, et al.
Published: (2014-04-01)

First-line treatment of chronic lymphocytic leukemia with three combined chemotherapy regimens
by: Matevž Škerget
Published: (2012-12-01)

Magnitude and causes of first-line antiretroviral therapy regimen changes among HIV patients in Ethiopia: a systematic review and meta-analysis
by: Zerihun Ataro, et al.
Published: (2019-11-01)

Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar.
by: Nang Thu Thu Kyaw, et al.
Published: (2015-01-01)

Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
by: A V Kravchenko
Published: (2013-11-01)